Rapid nanobody-based imaging of mesothelin expressing malignancies compatible with blocking therapeutic antibodies

INTRODUCTION: Mesothelin (MSLN) is overexpressed in a wide variety of cancers with few therapeutic options and has recently emerged as an attractive target for cancer therapy, with a large number of approaches currently under preclinical and clinical investigation. In this respect, developing mesoth...

Descripción completa

Detalles Bibliográficos
Autores principales: Benloucif, Abdennour, Meyer, Damien, Balasse, Laure, Goubard, Armelle, Danner, Lucile, Bouhlel, Ahlem, Castellano, Rémy, Guillet, Benjamin, Chames, Patrick, Kerfelec, Brigitte
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10303918/
https://www.ncbi.nlm.nih.gov/pubmed/37388728
http://dx.doi.org/10.3389/fimmu.2023.1200652

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10303918/
https://www.ncbi.nlm.nih.gov/pubmed/37388728
http://dx.doi.org/10.3389/fimmu.2023.1200652

Ejemplares similares